Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 154 articles:
HTML format
Text format



Single Articles


    January 2018
  1. SHAHZAD MMK, Felder M, Ludwig K, Van Galder HR, et al
    Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src.
    PLoS One. 2018;13:e0189524.
    PubMed     Text format     Abstract available


  2. WANG KH, Wang YM, Chiu LH, Chen TC, et al
    Optical imaging of ovarian cancer using a matrix metalloproteinase-3-sensitive near-infrared fluorescent probe.
    PLoS One. 2018;13:e0192047.
    PubMed     Text format     Abstract available


  3. LUO H, Xu X, Ye M, Sheng B, et al
    The prognostic value of HER2 in ovarian cancer: A meta-analysis of observational studies.
    PLoS One. 2018;13:e0191972.
    PubMed     Text format     Abstract available


  4. ZHANG R, Pu W, Zhang S, Chen L, et al
    Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial.
    PLoS One. 2018;13:e0191756.
    PubMed     Text format     Abstract available


  5. SINGH G, Roy J, Rout P, Mallick B, et al
    Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers.
    PLoS One. 2018;13:e0190485.
    PubMed     Text format     Abstract available


  6. HOU S, Dai J
    Transcriptome-based signature predicts the effect of taxol in serous ovarian cancer.
    PLoS One. 2018;13:e0192812.
    PubMed     Text format     Abstract available


  7. HYLER AR, Baudoin NC, Brown MS, Stremler MA, et al
    Fluid shear stress impacts ovarian cancer cell viability, subcellular organization, and promotes genomic instability.
    PLoS One. 2018;13:e0194170.
    PubMed     Text format     Abstract available


  8. NOEL-MACDONNELL JR, Usset J, Goode EL, Fridley BL, et al
    Assessment of data transformations for model-based clustering of RNA-Seq data.
    PLoS One. 2018;13:e0191758.
    PubMed     Text format     Abstract available


  9. CHUDECKA-GLAZ A, Cymbaluk-Ploska A, Wezowska M, Menkiszak J, et al
    Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?
    PLoS One. 2018;13:e0194270.
    PubMed     Text format     Abstract available


  10. CHANG LC, Huang CF, Lai MS, Shen LJ, et al
    Prognostic factors in epithelial ovarian cancer: A population-based study.
    PLoS One. 2018;13:e0194993.
    PubMed     Text format     Abstract available


  11. NEYT M, Vlayen J, Devriese S, Camberlin C, et al
    First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
    PLoS One. 2018;13:e0195134.
    PubMed     Text format     Abstract available


  12. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeillinger R, et al
    Correction: Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2018;13:e0196142.
    PubMed     Text format     Abstract available


  13. ZHANG T, Xu J, Deng S, Zhou F, et al
    Core signaling pathways in ovarian cancer stem cell revealed by integrative analysis of multi-marker genomics data.
    PLoS One. 2018;13:e0196351.
    PubMed     Text format     Abstract available


  14. AITHAL A, Junker WM, Kshirsagar P, Das S, et al
    Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
    PLoS One. 2018;13:e0193907.
    PubMed     Text format     Abstract available


  15. ALEMAR B, Gregorio C, Herzog J, Matzenbacher Bittar C, et al
    Correction: BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    PLoS One. 2018;13:e0197529.
    PubMed     Text format     Abstract available


  16. HECKL M, Schmoeckel E, Hertlein L, Rottmann M, et al
    The ARID1A, p53 and ss-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    PLoS One. 2018;13:e0192881.
    PubMed     Text format     Abstract available


  17. HE X, Yang K, Wang H, Chen X, et al
    Expression and clinical significance of survivin in ovarian cancer: A meta-analysis.
    PLoS One. 2018;13:e0194463.
    PubMed     Text format     Abstract available


    January 2017
  18. FAKKERT IE, van der Veer E, Abma EM, Lefrandt JD, et al
    Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.
    PLoS One. 2017;12:e0169673.
    PubMed     Text format     Abstract available


  19. SEEBACHER V, Reinthaller A, Koelbl H, Concin N, et al
    The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.
    PLoS One. 2017;12:e0169272.
    PubMed     Text format     Abstract available


  20. LEE HH, Bellat V, Law B
    Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer.
    PLoS One. 2017;12:e0171044.
    PubMed     Text format     Abstract available


  21. BAI L, Wang H, Wang AH, Zhang LY, et al
    MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.
    PLoS One. 2017;12:e0173912.
    PubMed     Text format     Abstract available


  22. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
    PLoS One. 2017;12:e0174300.
    PubMed     Text format     Abstract available


  23. MA Z, Wang X, He J, Xia J, et al
    Increased expression of protein kinase CK2alpha correlates with poor patient prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0174037.
    PubMed     Text format     Abstract available


  24. COZZI GD, Levinson RT, Toole H, Snyder MR, et al
    Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0175119.
    PubMed     Text format     Abstract available


  25. BRENCICOVA E, Jagger AL, Evans HG, Georgouli M, et al
    Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
    PLoS One. 2017;12:e0175712.
    PubMed     Text format     Abstract available


  26. GRAUMANN R, Di Capua GA, Oyarzun JE, Vasquez MA, et al
    Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.
    PLoS One. 2017;12:e0177244.
    PubMed     Text format     Abstract available


  27. CHEN WC, Qiu JT, Lai CH, Huang HJ, et al
    Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
    PLoS One. 2017;12:e0175703.
    PubMed     Text format     Abstract available


  28. LIU C, Zhang Y, Jiang H, Wu H, et al
    Association between social support and post-traumatic stress disorder symptoms among Chinese patients with ovarian cancer: A multiple mediation model.
    PLoS One. 2017;12:e0177055.
    PubMed     Text format     Abstract available



  29. Correction: Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0178965.
    PubMed     Text format     Abstract available


  30. STAFFORD JL, Dyson G, Levin NK, Chaudhry S, et al
    Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
    PLoS One. 2017;12:e0178450.
    PubMed     Text format     Abstract available


  31. ZHANG W, Su J, Xu H, Yu S, et al
    Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    PLoS One. 2017;12:e0179672.
    PubMed     Text format     Abstract available


  32. BJERSAND K, Seidal T, Sundstrom-Poromaa I, Akerud H, et al
    The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0179363.
    PubMed     Text format     Abstract available


  33. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2017;12:e0179501.
    PubMed     Text format     Abstract available


  34. WAN X, Bovornchutichai P, Cui Z, O'Neill E, et al
    Morphological analysis of human umbilical vein endothelial cells co-cultured with ovarian cancer cells in 3D: An oncogenic angiogenesis assay.
    PLoS One. 2017;12:e0180296.
    PubMed     Text format     Abstract available


  35. CHAO TK, Huang TS, Liao YP, Huang RL, et al
    Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    PLoS One. 2017;12:e0182166.
    PubMed     Text format     Abstract available


  36. LANDSKRON J, Kraggerud SM, Wik E, Dorum A, et al
    C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
    PLoS One. 2017;12:e0182030.
    PubMed     Text format     Abstract available


  37. PAULLIN T, Powell C, Menzie C, Hill R, et al
    Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses.
    PLoS One. 2017;12:e0182930.
    PubMed     Text format     Abstract available


  38. ROZENBLUM E, Sotelo-Silveira JR, Kim GY, Zhu JY, et al
    Novel near-diploid ovarian cancer cell line derived from a highly aneuploid metastatic ovarian tumor.
    PLoS One. 2017;12:e0182610.
    PubMed     Text format     Abstract available


  39. PETERS IT, van Zwet EW, Smit VT, Liefers GJ, et al
    Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.
    PLoS One. 2017;12:e0168277.
    PubMed     Text format     Abstract available


  40. ZHU J, Wen H, Ju X, Bi R, et al
    Clinical Significance of Programmed Death Ligand1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
    PLoS One. 2017;12:e0170879.
    PubMed     Text format     Abstract available


  41. SEEBACHER V, Aust S, D'Andrea D, Grimm C, et al
    Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.
    PLoS One. 2017;12:e0182383.
    PubMed     Text format     Abstract available


  42. HAIMOVICH JS, Venkatesh AK, Shojaee A, Coppi A, et al
    Discovery of temporal and disease association patterns in condition-specific hospital utilization rates.
    PLoS One. 2017;12:e0172049.
    PubMed     Text format     Abstract available


  43. JIA ZH, Jia Y, Guo FJ, Chen J, et al
    Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer.
    PLoS One. 2017;12:e0183622.
    PubMed     Text format     Abstract available


  44. CHUNG YS, Kim YJ, Lee I, Lee JY, et al
    Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
    PLoS One. 2017;12:e0183754.
    PubMed     Text format     Abstract available


  45. ZHANG H, Lu J, Lu Y, Zhou J, et al
    Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma.
    PLoS One. 2017;12:e0177520.
    PubMed     Text format     Abstract available


  46. ROSSO M, Majem B, Devis L, Lapyckyj L, et al
    E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.
    PLoS One. 2017;12:e0184439.
    PubMed     Text format     Abstract available


  47. AYYAGARI VN, Diaz-Sylvester PL, Hsieh TJ, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
    PLoS One. 2017;12:e0185111.
    PubMed     Text format     Abstract available


  48. GRANATA V, Fusco R, Catalano O, Avallone A, et al
    Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.
    PLoS One. 2017;12:e0179951.
    PubMed     Text format     Abstract available


  49. YANAGIDA S, Anglesio MS, Nazeran TM, Lum A, et al
    Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.
    PLoS One. 2017;12:e0178989.
    PubMed     Text format     Abstract available


  50. LIN KT, Sun SP, Wu JI, Wang LH, et al
    Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.
    PLoS One. 2017;12:e0178937.
    PubMed     Text format     Abstract available


  51. SUNG PL, Wen KC, Chen YJ, Chao TC, et al
    The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    PLoS One. 2017;12:e0185615.
    PubMed     Text format     Abstract available


  52. ZHU XM, Sun WF
    Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review.
    PLoS One. 2017;12:e0185456.
    PubMed     Text format     Abstract available


  53. TAO X, Chen L, Ge S, Cai L, et al
    Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: A meta-analysis.
    PLoS One. 2017;12:e0177426.
    PubMed     Text format     Abstract available


  54. HARTER P, Hauke J, Heitz F, Reuss A, et al
    Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    PLoS One. 2017;12:e0186043.
    PubMed     Text format     Abstract available


  55. GUO Z, Wang X, Cheng D, Xia Z, et al
    Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.
    PLoS One. 2017;12:e0186965.
    PubMed     Text format     Abstract available


  56. VALIANATOS G, Valcikova B, Growkova K, Verlande A, et al
    A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.
    PLoS One. 2017;12:e0185801.
    PubMed     Text format     Abstract available


  57. FORNARO L, Vivaldi C, Lin D, Xue H, et al
    Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation.
    PLoS One. 2017;12:e0182818.
    PubMed     Text format     Abstract available


  58. YANG L, Zhang B, Xing G, Du J, et al
    Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2017;12:e0186725.
    PubMed     Text format     Abstract available


  59. GENG X, Liu Y, Diersch S, Kotzsch M, et al
    Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.
    PLoS One. 2017;12:e0186847.
    PubMed     Text format     Abstract available


  60. QIN L, Li T, Liu Y
    High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer.
    PLoS One. 2017;12:e0187385.
    PubMed     Text format     Abstract available


  61. CHESNAIS M, Lecuru F, Mimouni M, Ngo C, et al
    A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
    PLoS One. 2017;12:e0187245.
    PubMed     Text format     Abstract available


  62. ALEMAR B, Gregorio C, Herzog J, Matzenbacher Bittar C, et al
    BRCA1 and BRCA2 mutational profile and prevalence in hereditary breast and ovarian cancer (HBOC) probands from Southern Brazil: Are international testing criteria appropriate for this specific population?
    PLoS One. 2017;12:e0187630.
    PubMed     Text format     Abstract available


  63. GSCHWANTLER-KAULICH D, Weingartshofer S, Rappaport-Furhauser C, Zeilinger R, et al
    Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.
    PLoS One. 2017;12:e0189641.
    PubMed     Text format     Abstract available


  64. KUROKI LM, Jin X, Dmitriev IP, Kashentseva EA, et al
    Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.
    PLoS One. 2017;12:e0190125.
    PubMed     Text format     Abstract available


  65. COUTTENIER A, Lacroix O, Vaes E, Cardwell CR, et al
    Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study.
    PLoS One. 2017;12:e0189233.
    PubMed     Text format     Abstract available


  66. OBATA T, Nakamura M, Mizumoto Y, Iizuka T, et al
    Dual expression of immunoreactive estrogen receptor beta and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
    PLoS One. 2017;12:e0188641.
    PubMed     Text format     Abstract available


  67. JIN D, Lee H
    FGMD: A novel approach for functional gene module detection in cancer.
    PLoS One. 2017;12:e0188900.
    PubMed     Text format     Abstract available


  68. CHEN Y, Bieber MM, Bhat NM, Teng NNH, et al
    Ovarian carcinoma glyco-antigen targeted by human IgM antibody.
    PLoS One. 2017;12:e0187222.
    PubMed     Text format     Abstract available


    January 2016
  69. HONG H, Brown CE, Ostberg JR, Priceman SJ, et al
    L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.
    PLoS One. 2016;11:e0146885.
    PubMed     Text format     Abstract available


  70. VIDAL F, Guerby P, Luyckx M, Haddad P, et al
    Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?
    PLoS One. 2016;11:e0147787.
    PubMed     Text format     Abstract available


  71. WILLIS S, Villalobos VM, Gevaert O, Abramovitz M, et al
    Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0149183.
    PubMed     Text format     Abstract available


  72. HUA X, Yu L, You R, Yang Y, et al
    Association among Dietary Flavonoids, Flavonoid Subclasses and Ovarian Cancer Risk: A Meta-Analysis.
    PLoS One. 2016;11:e0151134.
    PubMed     Text format     Abstract available


  73. LEHTINEN L, Vesterkvist P, Roering P, Korpela T, et al
    REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.
    PLoS One. 2016;11:e0151590.
    PubMed     Text format     Abstract available


  74. XIA Y, Chang T, Wang Y, Liu Y, et al
    Correction: YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients.
    PLoS One. 2016;11:e0152712.
    PubMed     Text format     Abstract available


  75. RAHMAN MA, Ramli F, Karimian H, Dehghan F, et al
    Artonin E Induces Apoptosis via Mitochondrial Dysregulation in SKOV-3 Ovarian Cancer Cells.
    PLoS One. 2016;11:e0151466.
    PubMed     Text format     Abstract available


  76. ZUBERI M, Khan I, Mir R, Gandhi G, et al
    Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.
    PLoS One. 2016;11:e0153902.
    PubMed     Text format     Abstract available


  77. CHOI JI, Park SH, Lee HJ, Lee DW, et al
    Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells.
    PLoS One. 2016;11:e0155052.
    PubMed     Text format     Abstract available


  78. ALAEE M, Danesh G, Pasdar M
    Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53.
    PLoS One. 2016;11:e0154323.
    PubMed     Text format     Abstract available


  79. NORDIN N, Fadaeinasab M, Mohan S, Mohd Hashim N, et al
    Pulchrin A, a New Natural Coumarin Derivative of Enicosanthellum pulchrum, Induces Apoptosis in Ovarian Cancer Cells via Intrinsic Pathway.
    PLoS One. 2016;11:e0154023.
    PubMed     Text format     Abstract available


  80. PAINE MR, Kim J, Bennett RV, Parry RM, et al
    Whole Reproductive System Non-Negative Matrix Factorization Mass Spectrometry Imaging of an Early-Stage Ovarian Cancer Mouse Model.
    PLoS One. 2016;11:e0154837.
    PubMed     Text format     Abstract available


  81. MACLEAN JA 2ND, King ML, Okuda H, Hayashi K, et al
    WNT7A Regulation by miR-15b in Ovarian Cancer.
    PLoS One. 2016;11:e0156109.
    PubMed     Text format     Abstract available


  82. MARTIN SD, Brown SD, Wick DA, Nielsen JS, et al
    Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    PLoS One. 2016;11:e0155189.
    PubMed     Text format     Abstract available


  83. ZHOU Y, Xu X, Lv H, Wen Q, et al
    The Long Noncoding RNA MALAT-1 Is Highly Expressed in Ovarian Cancer and Induces Cell Growth and Migration.
    PLoS One. 2016;11:e0155250.
    PubMed     Text format     Abstract available


  84. FENG Z, Wen H, Bi R, Ju X, et al
    Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer.
    PLoS One. 2016;11:e0156101.
    PubMed     Text format     Abstract available


  85. SOSULSKI A, Horn H, Zhang L, Coletti C, et al
    CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
    PLoS One. 2016;11:e0156595.
    PubMed     Text format     Abstract available


  86. ZHOU Q, Li W, Leng B, Zheng W, et al
    Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0155495.
    PubMed     Text format     Abstract available


  87. TRACHANA SP, Pilalis E, Gavalas NG, Tzannis K, et al
    The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.
    PLoS One. 2016;11:e0156403.
    PubMed     Text format     Abstract available


  88. BOTESTEANU DA, Lee JM, Levy D
    Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection.
    PLoS One. 2016;11:e0156661.
    PubMed     Text format     Abstract available


  89. HELLAND O, Popa M, Bischof K, Gjertsen BT, et al
    The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    PLoS One. 2016;11:e0158208.
    PubMed     Text format     Abstract available


  90. VIGORITO E, Kuchenbaecker KB, Beesley J, Adlard J, et al
    Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    PLoS One. 2016;11:e0158801.
    PubMed     Text format     Abstract available


  91. TAKAHASHI R, Mabuchi S, Kawano M, Sasano T, et al
    Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    PLoS One. 2016;11:e0151050.
    PubMed     Text format     Abstract available


  92. KIM HJ, Lee SY, Shin YR, Park CS, et al
    The Value of Diffusion-Weighted Imaging in the Differential Diagnosis of Ovarian Lesions: A Meta-Analysis.
    PLoS One. 2016;11:e0149465.
    PubMed     Text format     Abstract available


  93. YOSHIDA M, Taguchi A, Kawana K, Adachi K, et al
    Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    PLoS One. 2016;11:e0160330.
    PubMed     Text format     Abstract available


  94. CHOWANADISAI W, Messerli SM, Miller DH, Medina JE, et al
    Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors.
    PLoS One. 2016;11:e0151089.
    PubMed     Text format     Abstract available


  95. WANG T, Li W, Wu X, Yin B, et al
    Tubo-Ovarian Abscess (with/without Pseudotumor Area) Mimicking Ovarian Malignancy: Role of Diffusion-Weighted MR Imaging with Apparent Diffusion Coefficient Values.
    PLoS One. 2016;11:e0149318.
    PubMed     Text format     Abstract available


  96. PINTO P, Peixoto A, Santos C, Rocha P, et al
    Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
    PLoS One. 2016;11:e0161438.
    PubMed     Text format     Abstract available


  97. TALHOUK A, Kommoss S, Mackenzie R, Cheung M, et al
    Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction.
    PLoS One. 2016;11:e0153844.
    PubMed     Text format     Abstract available


  98. SHAH JS, Soon PS, Marsh DJ
    Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs.
    PLoS One. 2016;11:e0153200.
    PubMed     Text format     Abstract available


  99. TUMBARELLO DA, Andrews MR, Brenton JD
    SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
    PLoS One. 2016;11:e0162698.
    PubMed     Text format     Abstract available


  100. XIAO X, Cai F, Niu X, Shi H, et al
    Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies.
    PLoS One. 2016;11:e0163257.
    PubMed     Text format     Abstract available


  101. LI L, Luo Q, Xie Z, Li G, et al
    Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer.
    PLoS One. 2016;11:e0163447.
    PubMed     Text format     Abstract available


  102. IGNACIO RM, Kabir SM, Lee ES, Adunyah SE, et al
    NF-kappaB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
    PLoS One. 2016;11:e0164189.
    PubMed     Text format     Abstract available


  103. POCHECHUEVA T, Chinarev A, Schoetzau A, Fedier A, et al
    Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
    PLoS One. 2016;11:e0164230.
    PubMed     Text format     Abstract available


  104. FEDOSEIENKO A, Wieringa HW, Wisman GB, Duiker E, et al
    Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
    PLoS One. 2016;11:e0165385.
    PubMed     Text format     Abstract available


  105. SUN S, Cai J, Yang Q, Zhu Y, et al
    Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0166058.
    PubMed     Text format     Abstract available


  106. PENNINGTON M, Gentry-Maharaj A, Karpinskyj C, Miners A, et al
    Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    PLoS One. 2016;11:e0165539.
    PubMed     Text format     Abstract available


  107. RASOOL M, Malik A, Basit Ashraf MA, Parveen G, et al
    Evaluation of Matrix Metalloproteinases, Cytokines and Their Potential Role in the Development of Ovarian Cancer.
    PLoS One. 2016;11:e0167149.
    PubMed     Text format     Abstract available


  108. POWELL CD, Paullin TR, Aoisa C, Menzie CJ, et al
    The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.
    PLoS One. 2016;11:e0168389.
    PubMed     Text format     Abstract available


  109. TAO F, Ruan S, Liu W, Wang L, et al
    Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2016;11:e0168892.
    PubMed     Text format     Abstract available


    January 2015
  110. LI N, Yang L, Wang H, Yi T, et al
    MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    PLoS One. 2015;10:e0128886.
    PubMed     Text format     Abstract available


  111. JANATOVA M, Soukupova J, Stribrna J, Kleiblova P, et al
    Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    PLoS One. 2015;10:e0127711.
    PubMed     Text format     Abstract available


  112. KWIATKOWSKI F, Arbre M, Bidet Y, Laquet C, et al
    BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.
    PLoS One. 2015;10:e0127363.
    PubMed     Text format     Abstract available


  113. CHORNOKUR G, Lin HY, Tyrer JP, Lawrenson K, et al
    Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.
    PLoS One. 2015;10:e0128106.
    PubMed     Text format     Abstract available


  114. LANG F, Qin Z, Li F, Zhang H, et al
    Apoptotic Cell Death Induced by Resveratrol Is Partially Mediated by the Autophagy Pathway in Human Ovarian Cancer Cells.
    PLoS One. 2015;10:e0129196.
    PubMed     Text format     Abstract available


  115. TUMMERS QR, Hoogstins CE, Peters AA, de Kroon CD, et al
    The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer.
    PLoS One. 2015;10:e0129766.
    PubMed     Text format     Abstract available


  116. RAVOORI MK, Nishimura M, Singh SP, Lu C, et al
    Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
    PLoS One. 2015;10:e0131095.
    PubMed     Text format     Abstract available


  117. DU Y, Feng J, Wang R, Zhang H, et al
    Effects of Flavonoids from Potamogeton crispus L. on Proliferation, Migration, and Invasion of Human Ovarian Cancer Cells.
    PLoS One. 2015;10:e0130685.
    PubMed     Text format     Abstract available


  118. ZHOU Y, Bian B, Yuan X, Xie G, et al
    Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2015;10:e0130873.
    PubMed     Text format     Abstract available


  119. QIN DJ, Tang CX, Yang L, Lei H, et al
    Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells.
    PLoS One. 2015;10:e0132337.
    PubMed     Text format     Abstract available


  120. BOBBS A, Gellerman K, Hallas WM, Joseph S, et al
    ARID3B Directly Regulates Ovarian Cancer Promoting Genes.
    PLoS One. 2015;10:e0131961.
    PubMed     Text format     Abstract available


  121. MO L, Pospichalova V, Huang Z, Murphy SK, et al
    Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
    PLoS One. 2015;10:e0131579.
    PubMed     Text format     Abstract available


  122. ZHANG S, Lu Z, Mao W, Ahmed AA, et al
    CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
    PLoS One. 2015;10:e0131833.
    PubMed     Text format     Abstract available


  123. HARAGUCHI M, Sato M, Ozawa M
    CRISPR/Cas9n-Mediated Deletion of the Snail 1Gene (SNAI1) Reveals Its Role in Regulating Cell Morphology, Cell-Cell Interactions, and Gene Expression in Ovarian Cancer (RMG-1) Cells.
    PLoS One. 2015;10:e0132260.
    PubMed     Text format     Abstract available


  124. LEE YC, Lee CH, Tsai HP, An HW, et al
    Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
    PLoS One. 2015;10:e0132579.
    PubMed     Text format     Abstract available


  125. CHAO A, Tsai CL, Jung SM, Chuang WC, et al
    BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer.
    PLoS One. 2015;10:e0133081.
    PubMed     Text format     Abstract available


  126. NIU L, Li S, Liang H, Li H, et al
    The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.
    PLoS One. 2015;10:e0135822.
    PubMed     Text format     Abstract available


  127. BELOTTE J, Fletcher NM, Saed MG, Abusamaan MS, et al
    A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.
    PLoS One. 2015;10:e0135739.
    PubMed     Text format     Abstract available


  128. GRANADOS ML, Hudson LG, Samudio-Ruiz SL
    Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
    PLoS One. 2015;10:e0136893.
    PubMed     Text format     Abstract available


  129. QIAN X, Qin J, Pan S, Li X, et al
    Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0139026.
    PubMed     Text format     Abstract available


  130. YUAN C, Liu X, Liu X, Yang N, et al
    The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.
    PLoS One. 2015;10:e0138692.
    PubMed     Text format     Abstract available


  131. DEVAPATLA B, Sharma A, Woo S
    CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    PLoS One. 2015;10:e0139237.
    PubMed     Text format     Abstract available


  132. AUST S, Knogler T, Pils D, Obermayr E, et al
    Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer.
    PLoS One. 2015;10:e0140403.
    PubMed     Text format     Abstract available


  133. GARZIERA M, Montico M, Bidoli E, Scalone S, et al
    Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
    PLoS One. 2015;10:e0140351.
    PubMed     Text format     Abstract available


  134. BENSON EA, Skaar TC, Liu Y, Nephew KP, et al
    Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    PLoS One. 2015;10:e0141279.
    PubMed     Text format     Abstract available


  135. LIU J, Bai J, Jiang G, Li X, et al
    Anti-Tumor Effect of Pinus massoniana Bark Proanthocyanidins on Ovarian Cancer through Induction of Cell Apoptosis and Inhibition of Cell Migration.
    PLoS One. 2015;10:e0142157.
    PubMed     Text format     Abstract available


  136. CHAO WR, Lee MY, Ruan A, Sheng HP, et al
    Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.
    PLoS One. 2015;10:e0142135.
    PubMed     Text format     Abstract available


  137. WU N, Wei J, Wang Y, Yan J, et al
    Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition.
    PLoS One. 2015;10:e0143659.
    PubMed     Text format     Abstract available


  138. PATHAK HB, Zhou Y, Sethi G, Hirst J, et al
    A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
    PLoS One. 2015;10:e0144126.
    PubMed     Text format     Abstract available


  139. QIAO JJ, Yu J, Yu Z, Li N, et al
    Contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors.
    PLoS One. 2015;10:e0118872.
    PubMed     Text format     Abstract available


  140. MISHRA EK, Corcoran JP, Hallifax RJ, Stradling J, et al
    Defining the minimal important difference for the visual analogue scale assessing dyspnea in patients with malignant pleural effusions.
    PLoS One. 2015;10:e0123798.
    PubMed     Text format     Abstract available


  141. VERMEERSCH KA, Wang L, Mezencev R, McDonald JF, et al
    OVCAR-3 spheroid-derived cells display distinct metabolic profiles.
    PLoS One. 2015;10:e0118262.
    PubMed     Text format     Abstract available


  142. EULENBURG C, Mahner S, Woelber L, Wegscheider K, et al
    A systematic model specification procedure for an illness-death model without recovery.
    PLoS One. 2015;10:e0123489.
    PubMed     Text format     Abstract available


  143. RAO TD, Tian H, Ma X, Yan X, et al
    Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    PLoS One. 2015;10:e0126633.
    PubMed     Text format     Abstract available


  144. GLASER G, Weroha SJ, Becker MA, Hou X, et al
    Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    PLoS One. 2015;10:e0126867.
    PubMed     Text format     Abstract available


  145. CHEN S, Chen X, Xiu YL, Sun KX, et al
    Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
    PLoS One. 2015;10:e0125714.
    PubMed     Text format     Abstract available


  146. WANG X, Jiang P, Wang P, Yang CS, et al
    EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer.
    PLoS One. 2015;10:e0125402.
    PubMed     Text format     Abstract available


  147. KANG J, Lee HJ, Kim J, Lee JJ, et al
    Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma.
    PLoS One. 2015;10:e0118927.
    PubMed     Text format     Abstract available


  148. LINDEGREN S, Andrade LN, Back T, Machado CM, et al
    Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
    PLoS One. 2015;10:e0126298.
    PubMed     Text format     Abstract available


  149. YE S, Yang J, Cao D, Bai H, et al
    Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study.
    PLoS One. 2015;10:e0121818.
    PubMed     Text format     Abstract available


  150. PATTERSON SD, Rossi JM, Paweletz KL, Fitzpatrick VD, et al
    Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.
    PLoS One. 2015;10:e0122149.
    PubMed     Text format     Abstract available


  151. DE BOER E, Crane LM, van Oosten M, van der Vegt B, et al
    Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer.
    PLoS One. 2015;10:e0135012.
    PubMed     Text format     Abstract available


  152. SCHUMMER M, Thorpe J, Giraldez M, Bergan L, et al
    Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
    PLoS One. 2015;10:e0142911.
    PubMed     Text format     Abstract available


  153. KENMOGNE LC, Ayan D, Roy J, Maltais R, et al
    The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers.
    PLoS One. 2015;10:e0144890.
    PubMed     Text format     Abstract available


    January 2014
  154. JONSSON JM, Johansson I, Dominguez-Valentin M, Kimbung S, et al
    Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
    PLoS One. 2014;9:e107643.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: